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ORIGINAL INVESTIGATION
Calcium Plus Vitamin D Supplementation
and the Risk of Postmenopausal Weight Gain
Bette Caan, DrPH; Marian Neuhouser, PhD; Aaron Aragaki, MS; Cora Beth Lewis, MD; Rebecca Jackson, MD;
Meryl S. LeBoff, MD; Karen L. Margolis, MD; Lynda Powell, PhD; Gabriel Uwaifo, MD; Evelyn Whitlock, MD;
Judy Wylie-Rosett, EdD; Andrea LaCroix, PhD
Background: Obesity in the United States has in-
creased significantly during the past several decades. The
role of calcium in the maintenance of a healthy body
weight remains controversial.
Methods: A randomized, double-blinded, placebo-
controlled trial was performed with 36 282 postmeno-
pausal women, aged 50 to 79 years, who were already
enrolled in the dietary modification and/or hormone
therapy arms of the Women’s Health Initiative clinical
trial. Women were randomized at their first or second
annual visit to receive a dose of 1000 mg of elemental
calcium plus 400 IU of cholecalciferol (vitamin D) or pla-
cebo daily. Change in body weight was ascertained an-
nually for an average of 7 years.
Results: Women receiving calcium plus cholecalcif-
erol supplements vs women receiving placebo had a mini-
mal but consistent favorable difference in weight change
(mean difference, −0.13 kg; 95% confidence interval, −0.21
to −0.05;P =.001). After 3 years of follow-up, women with
daily calcium intakes less than 1200 mg at baseline who
were randomized to supplements were 11% less likely
to experience small weight gains (1-3 kg) and 11% less
likely to gain more moderate amounts of weight (3 kg)
(P for interaction for baseline calcium intake=.008).
Conclusion: Calcium plus cholecalciferol supplemen-
tation has a small effect on the prevention of weight gain,
which was observed primarily in women who reported
inadequate calcium intakes.
Trial Registration: clinicaltrials.gov Identifier:
NCT00000611
Arch Intern Med. 2007;167:893-902
T HE CENTERS FOR DISEASEControl and Prevention’sBehavioral Risk Factor Sur-veillance System1 reportedthat the proportion of
women between the ages of 50 and 79
years who are obese (body mass index
[BMI; calculated as weight in kilograms di-
vided by the square of height in meters]
30) increased by nearly 50% during the
1990s; however, more recent reports show
rates beginning to stabilize.2 During a
3-year follow-up period in a cohort of 3302
middle-aged women, the Study of Wom-
en’s Health Across the Nation3 found that
the mean weight and waist circumfer-
ence gains were 2.1 kg and 2.2 cm, re-
spectively. Other cohort studies4,5 have pre-
viously reported similar findings in
perimenopausal and postmenopausal
women. Age-related changes in body com-
position, metabolic factors, and hor-
mone levels, accompanied by declines in
physical activity, may provide the under-
lying mechanisms for the propensity to-
ward postmenopausal gains in fat mass and
replacement of lean tissue with adipose tis-
sue.4,6-8 Because weight loss or preven-
tion of weight gain is likely to have sig-
nificant health benefits for middle-aged
women,9,10 early to middle menopause may
be a critical period of life in which to slow
the trajectory of weight gain.
Some evidence exists that calcium and
vitamin D and foods rich in these nutri-
ents may have a role in effective weight
management. The biological rationale
comes from the observation that calcium
and 1,25-hydroxyvitamin D work in con-
cert to regulate lipid metabolism in adi-
pose cells,11,12 particularly by stimulating
fatty acid oxidation and suppressing lipo-
genesis. Additionally, calcium may de-
crease fatty acid absorption through the
formation of calcium and fatty acid “soaps”
in the intestine and increase fecal fat
losses.8,12-14 Studies11,15-18 in humans offer
suggestive, but not definitive,19 data to sup-
port these mechanisms, and a recent re-
port20 specifically supports the role of cal-
cium supplements in reducing weight gain
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among women approaching midlife. The scant pub-
lished data from intervention trials are also inconclu-
sive21; some suggest no relationship,22,23 whereas others
suggest a role for these nutrients in weight manage-
ment.8,24,25 Data from large randomized trials such as the
Women’s Health Initiative (WHI) (see boxed copy on page
901) offer an excellent opportunity to test the hypoth-
esis that calcium and vitamin D are associated with at-
tenuation of weight gain in postmenopausal women.
METHODS
STUDY POPULATION
Between October 29, 1993, and October 11, 1998, women were
recruited into the WHI randomized trials that assessed the risks
and benefits of hormone therapy (HT) and dietary modifica-
tion (DM). Eligible women were aged 50 to 79 years and were
postmenopausal. One year later, 36 282 of these participants
were recruited into a calcium plus cholecalciferol (vitamin D)
randomized trial, which was designed to test whether calcium
plus cholecalciferol supplementation would reduce the inci-
dence of hip fracture and colorectal cancer. Detailed eligibility
criteria and recruitment methods have previously been pub-
lished.26 Personal use of calcium (up to 1000 mg/d) and cho-
lecalciferol (up to 600 IU/d and, after 1999, up to 1000 IU/d)
was allowed. Among the total participants enrolled in the cal-
cium plus cholecalciferol randomized trial, 91.15% joined at
their first annual visit and 8.85% joined the following year.
Among the trial participants, 44.34% were in the HT trial, 69.48%
were in the DM trial, and 13.83% participated in both trials.
The protocol and consent forms were approved by the insti-
tutional review boards at participating institutions.
RANDOMIZATION, BLINDING, INTERVENTION,
AND FOLLOW-UP PROCEDURES
Eligible women were randomly assigned in a double-blind fash-
ion to supplement or placebo (provided by GlaxoSmithKline, Pitts-
burgh, Pa) in equal proportions using a permuted block algo-
rithm stratified by clinical center and age. Each active tablet
contained 500 mg of elemental calcium (as calcium carbonate)
and 200 IU of cholecalciferol. Participants were instructed to take
2 tablets per day in divided doses with meals to maximize ab-
sorption. Two years after randomization, cross-sectional com-
parison of serum concentrations of 25-hydroxyvitamin D from
227 women taking active supplements and 221 women taking
placebo revealed a statistically significant 28% higher serum con-
centration of 25-hydroxyvitamin D in women assigned to the ac-
tive calcium plus cholecalciferol group compared with those ran-
domized to the placebo group.
Telephone contact was made 4 weeks after calcium plus cho-
lecalciferol randomization and thereafter semiannually to as-
sess participant symptoms and reinforce adherence. Adher-
ence was assessed by weighing returned pill bottles at annual
clinic visits. Follow-up continued regardless of adherence to
the protocol until death, loss to follow-up, participant request
for no further contact, or study closeout.
Throughout the trial, women with intolerable gastrointes-
tinal tract symptoms were treated by reducing the number of
times per day or days per week that study medication was taken
without unblinding either the participant or the study staff. Use
of study pills was discontinued after report of kidney stones,
hypercalcemia, dialysis, calcitriol use, or personal supplemen-
tation of more than 1000 IU/d of cholecalciferol, again with-
out unblinding.
DATA COLLECTION
Prerandomization total daily calcium intake was the sum of di-
etary calcium assessed using the WHI food frequency question-
naire, an adaptation of the Block food frequency question-
naire,27 plus calcium from supplements in the previous 2 weeks,
plus calcium from prescription medications obtained through an
interviewer-administered medication survey. Total vitamin D in-
take was similarly determined from diet and supplement use.
Weight and height were obtained in a standardized man-
ner from all clinical trial participants at each annual visit. Weight
was measured with the study participant in light clothing on a
calibrated balance beam or digital scale and recorded to the near-
est one-tenth kilogram.
STATISTICAL ANALYSIS
The primary outcome measure was weight change: annual
weight measurements collected through 7 years of follow-up
minus the most recent weight measured before calcium plus
cholecalciferol randomization. All participants with at least 1
weight change measurement were included in the intent-to-
treat analysis using linear repeated-measures regression mod-
eling with an unstructured covariance matrix (SAS PROC
MIXED version 9.1; SAS Institute Inc, Cary, NC). Plots of lon-
gitudinal data are based on fitted means from these models in
which both treatment assignment and time are modeled as class
variables and treatment effect is allowed to vary with time (satu-
rated model). To assess whether the effect of calcium plus cho-
lecalciferol supplementation on weight change varied accord-
ing to baseline risk factors, including baseline calcium and
vitamin D intakes, the same models were extended and formal
tests of interactions were performed. To examine the effect of
nonadherence (to the calcium plus cholecalciferol supple-
ments or placebo), sensitivity analyses were conducted in which
participants were censored after their first annual visit at which
nonadherence, defined as the use of less than 80% of the study
pills, was detected. The risk of weight gain during follow-up
was examined by comparing those who gained weight (1 kg)
with a combined group that consisted of those who either lost
weight or remained weight stable (within 1 kg) using gen-
eralized estimating equations with a logit link function and un-
structured covariance matrix (SAS PROC GENMOD version
9.1; SAS Institute Inc). In a secondary analysis, we examined
the prevention of weight gain during a 3-year period after ran-
domization into the calcium plus cholecalciferol trial. Three
years after baseline appeared to be the point at which this post-
menopausal cohort transitioned from weight gain to weight loss
as part of the natural weight trajectory of aging. Using nomi-
nal multinomial logistic regression modeling, we estimated the
odds ratios (ORs) and their 95% confidence intervals (CIs) of
gaining small amounts of weight (1-3 kg) or moderate amounts
of weight (3 kg) compared with remaining weight stable (1
kg) or losing weight (1 kg) during this 3-year period.
RESULTS
BASELINE CHARACTERISTICS,
ADHERENCE, AND RETENTION
At randomization, 18 176 women were assigned to the
active calcium plus cholecalciferol supplementation and
18 106 to placebo. Baseline, demographic, medical, and
lifestyle characteristics, including calcium intakes, and
randomization into the HT and DM trials were similar
between groups (Table 1). Mean (SD) follow-up time
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Table 1. Characteristics of the 36 282 Participants in the Calcium With Cholecalciferol (Vitamin D) Trial at the Time of the Women’s
Health Initiative Screening, According to Randomly Assigned Group
Characteristic
Treatment Assignment
P
Value
Calcium and
Cholecalciferol Placebo
No. (%) No. (%)
Age group at screening, y .99*
50-54 2592 (14.26) 2561 (14.14)
55-59 4134 (22.74) 4135 (22.84)
60-69 8276 (45.53) 8243 (45.53)
70-79 3174 (17.46) 3167 (17.49)
Ethnicity .45*
White 15 047 (82.78) 15 106 (83.43)
Black 1682 (9.25) 1635 (9.03)
Hispanic 789 (4.34) 718 (3.97)
American Indian 77 (0.42) 72 (0.40)
Asian/Pacific Islander 369 (2.03) 353 (1.95)
Unknown 212 (1.17) 222 (1.23)
Educational level .94*
High school 4286 (23.74) 4289 (23.84)
School after high school† 7216 (39.96) 7156 (39.78)
College degree 6555 (36.30) 6543 (36.37)
BMI .26*
25 4974 (27.61) 5117 (28.51)
25 to 30 6409 (35.57) 6327 (35.26)
30 to 35 4037 (22.41) 3992 (22.24)
35 2621 (14.41) 2539 (13.99)
Smoking .31*
Never 9325 (51.85) 9428 (52.62)
Past 7255 (40.34) 7133 (39.81)
Current 1405 (7.81) 1356 (7.57)
Multivitamin use, with or without minerals 6419 (35.32) 6508 (35.94) .21*
Total calcium intake (dietary and supplements), mg .31*
600 3554 (19.94) 3447 (19.42)
600 to 1200 7265 (40.77) 7211 (40.62)
1200 7002 (39.29) 7095 (39.97)
Diet modification trial assignment .30*
Comparison 7827 (43.06) 7738 (42.74)
Intervention 4767 (26.23) 4878 (26.94)
Not randomized 5582 (30.71) 5490 (30.32)
Hormone therapy trial assignment .80*
CEE active 1531 (8.42) 1543 (8.52)
CEE placebo 1540 (8.47) 1562 (8.63)
CEE and MPA active 2508 (13.80) 2535 (14.00)
CEE and MPA placebo 2475 (13.62) 2395 (13.23)
Not randomized 10 122 (55.69) 10 071 (55.62)
Mean (SD) Mean (SD)
Waist, cm 88.9 (13.7) [n = 18 128] 88.8 (13.7) [n = 18 051] .46§
Weight, kg‡ 76.0 (16.9) [n = 18 129] 75.9 (17.1) [n = 18 055] .53§
BMI‡ 28.9 (6.0) [n = 18 016] 28.8 (6.0) [n = 17 946] .12§
Physical activity, METs/wk 10.7 (12.7) [n = 16 546] 10.6 (12.4) [n = 16 448] .60§
Dietary energy, kcal 1735 (752) [n = 18 126] 1738 (732) [n = 18 042] .75§
Dietary protein, g 72 (33) [n = 18 126] 72 (32) [n = 18 042] .88§
Dietary total carbohydrate, g 202 (87) [n = 18 126] 203 (87) [n = 18 042] .45§
Dietary total fat, g 70 (38) [n = 18 126] 70 (36) [n = 18 042] .96§
Calories from fat, % 36 (7) [n = 18 126] 36 (7) [n = 18 042] .52§
Dairy, medium servings per day 2 (1) [n = 17 821] 2 (1) [n = 17 753] .96§
Total calcium intake (supplements and dietary), mg 1148 (654) [n = 17 821] 1154 (658) [n = 17 753] .40§
Total cholecalciferol (supplements and dietary), µg 9 (7) [n = 17 821] 9 (7) [n = 17 753] .36§
Fruits and vegetables, medium servings per day 4 (2) [n = 17 821] 4 (2) [n = 17 753] .33§
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); CEE, conjugated equine estrogen;
MPA, medroxyprogesterone acetate; METs, metabolic equivalents.
*From a 2 test of association.
†Includes vocational or training school after high school graduation or some college or associate’s degree.
‡For weight and BMI, we present measurements at randomization into the calcium and cholecalciferol trial.
§From a 2-sample t test.
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was 7.0 (1.4) years. At screening for the WHI, the mean
(SD) age was 62.4 (6.9) years, and mean (SD) BMI was
29.0 (5.9). At baseline, 39.63% of the women met the cur-
rent recommended daily intake (RDI) of 1200 mg/d of
calcium from supplements and diet combined, 53.94%
reported any personal calcium supplementation, and
28.95% reported calcium supplementation of 500 mg or
more. Of the women randomized into the calcium plus
cholecalciferol trial, 26.58% had been randomly as-
signed to the low-fat intervention arm of the DM trial.
At the termination of the trial, 1551 participants
(4.27%) had died and 2.70% had withdrawn or been lost
to follow-up. In year 1, the proportion consuming 80%
or more of the study medication was 60.46% overall and
remained relatively stable through year 7, ranging from
55.73% to 62.87%, with small differences between treat-
ment groups. At least 66.18% took 50% or more of their
study medications through year 7.
WEIGHT CHANGE DURING THE
POSTMENOPAUSAL YEARS
Figure 1 demonstrates the variation by age in the natu-
ral trajectory of weight change during the 7-year fol-
low-up period. Postmenopausal women experience slow
but steady gains until approximately 60 years of age, at
which time they begin to stabilize for a period. They then
start to lose weight, beginning in their middle to late 60s,
and continue to lose weight throughout their seventh de-
cade. The youngest postmenopausal women (aged 50-54
years) experienced the largest mean weight gain (2.10 kg)
and were the only group to experience continuous weight
gain throughout the entire follow-up period. In contrast,
the oldest women (aged 70-79 years) were the only age
group to experience a continuous decrease in weight and
experienced the largest overall weight change of any age
group, with an average loss of 2.58 kg. The data presented
in Figure 1 are from those women randomized to the pla-
cebo arm of any WHI clinical trial intervention (HT, DM,
or calcium plus cholecalciferol) and thus are free of any
WHI-designed interventions that might modify weight.
WEIGHT CHANGE BY CALCIUM PLUS
CHOLECALCIFEROL STATUS
Women randomized to the calcium plus cholecalciferol
supplements had smaller average annual weight gains than
women assigned to placebo (Table 2 and Figure 2A).
The small difference between treatment assignments at
the first year did not appear to increase linearly with time
(P=.99). The mean difference between the treatment
groups, all in favor of calcium plus cholecalciferol, was
−0.13 kg (P=.001). Women who were the most adher-
ent (consuming 80% of their pills during follow-up)
had a mean difference of −0.14 kg of weight change
(P.001). Women who entered the trial with intakes of
calcium lower than the current RDI (1200 mg) had a
mean difference between treatment groups of −0.19 kg
(Figure 2B), whereas no significant benefit was seen for
women whose initial calcium intakes were at or greater
than the RDI (1200 mg) (P for interaction=.09). When
calcium intakes lower than the RDI were divided fur-
ther into quartiles, no evidence was found that the effect
of the intervention was more pronounced in those who
reported more marginal intakes (data not shown). Women
who were heavier also tended to have a slightly higher
benefit (P for interaction=.04). Treatment effects did not
vary by age or any of the other 12 subgroups of baseline
characteristics tested (Table 2).
PREVENTION OF WEIGHT GAIN
At 3 years after randomization, compared with women
taking placebo, women randomized to the active inter-
vention had a lower risk of gaining weight in both small
amounts (1-3 kg) (OR, 0.95; 95% CI, 0.90-1.01) and mod-
erate amounts (3 kg) (OR, 0.94; 95% CI, 0.90-0.99)
and a higher likelihood of remaining stable (1 kg) or
losing weight (1 kg) (Table 3). Results were similar
for the risk of weight gain during the entire 7-year trial
(OR, 0.96; 95% CI, 0.93-0.99; P=.005 for1-kg gain vs
weight stable or weight loss).
Treatment effects were primarily seen in women who
at baseline had calcium intakes less than 1200 mg; those
women had an 11% lower risk of gaining 1 to 3 kg (OR,
0.89; 95% CI, 0.83-0.96) and an 11% lower risk of gaining
more than 3 kg (OR, 0.89; 95% CI, 0.84-0.95), whereas
women whose intakes were greater than 1200 mg/d were
unaffected by treatment (P for interaction=.008). Further
dividing women who reported intakes lower than the RDI
did not demonstrate a more pronounced treatment effect
for women with more marginal intakes (data not shown).
No other interactions were observed (Table 3).
COMMENT
We found significantly smaller, albeit modest, weight in-
creases and a significantly lower risk of weight gain in
3
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Figure 1. Weight change by age for all 3 trials for participants who were
either randomized to placebo or not randomized.
(REPRINTED) ARCH INTERN MED/ VOL 167, MAY 14, 2007 WWW.ARCHINTERNMED.COM
896
©2007 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a University of California - San Diego User  on 07/01/2019
Table 2. Mean Difference in Weight Change During Follow-up: Overall and by Baseline Subgroups
Variable Mean Difference (Range) P Value*
Overall effect of calcium and cholecalciferol −0.13 (−0.21 to −0.05) .001†
Age at screening, y .98
50-54 −0.24 (−0.45 to −0.03)
55-59 −0.08 (−0.24 to 0.09)
60-69 −0.15 (−0.27 to −0.03)
70-79 −0.10 (−0.29 to 0.09)
Ethnicity .38
White −0.13 (−0.22 to −0.04)
Black −0.32 (−0.59 to −0.06)
Hispanic −0.08 (−0.48 to 0.32)
American Indian −0.56 (−1.81 to 0.69)
Asian/Pacific Islander 0.19 (−0.37 to 0.75)
Unknown 0.33 (−0.40 to 1.07)
Educational level .45
High school −0.13 (−0.30 to 0.03)
School after high school‡ −0.08 (−0.21 to 0.05)
College degree −0.20 (−0.33 to −0.07)
BMI .04
25 −0.08 (−0.23 to 0.06)
25 to30 −0.09 (−0.22 to 0.04)
30 to35 −0.23 (−0.40 to −0.06)
35 −0.17 (−0.38 to 0.04)
Waist circumference, cm .96
88 −0.16 (−0.27 to −0.05)
88 −0.12 (−0.23 to 0.00)
Total calcium intake (dietary and supplements), mg .09
1200 −0.19 (−0.29 to −0.09)
1200 −0.05 (−0.17 to 0.08)
Total cholecalciferol intake (diet and supplements), IU .37
400 −0.16 (−0.27 to −0.06)
400 −0.09 (−0.21 to 0.03)
Energy intake, kcal .13
1382.1 −0.17 (−0.31 to −0.03)
1382.1-1909.5 −0.17 (−0.31 to −0.03)
1909.5 −0.06 (−0.20 to 0.08)
Energy from fat, % .90
33.5 −0.11 (−0.25 to 0.03)
33.5-38.5 −0.09 (−0.23 to 0.05)
38.5 −0.20 (−0.34 to −0.06)
Fruits and vegetables, medium servings per day .90
2.7 −0.13 (−0.27 to 0.01)
2.7-4.3 −0.14 (−0.28 to 0.00)
4.3 −0.15 (−0.29 to −0.01)
Smoking .21
Never −0.17 (−0.28 to −0.06)
Past −0.07 (−0.20 to 0.05)
Current −0.34 (−0.63 to −0.04)
Physical activity, METs/wk .82
3 −0.16 (−0.30 to −0.01)
3-11.75 −0.14 (−0.29 to 0.00)
11.75 −0.11 (−0.26 to 0.03)
DM arm§ .60
Control −0.12 (−0.24 to 0.00)
Intervention −0.07 (−0.22 to 0.09)
HT arm  .42
E alone −0.33 (−0.62 to −0.05)
E alone placebo −0.03 (−0.31 to 0.25)
E and P −0.14 (−0.36 to 0.08)
E and P placebo −0.26 (−0.49 to −0.04)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); DM, dietary modification; E, estrogen;
HT, hormone therapy; METs, metabolic equivalents; P, progesterone.
*F test of interaction between calcium and cholecalciferol treatment and variable of interest from a linear repeated-measures model with an unstructured
correlation matrix.
†F test of main effect of calcium and cholecalciferol treatment from a linear repeated-measures model with an unstructured correlation matrix.
‡Includes vocational or training school after high school graduation or some college or associate’s degree.
§Subset (n = 25 210) of the calcium and cholecalciferol randomized trial; see Table 1 for details.
Subset (n = 16 089) of the calcium and cholecalciferol randomized trial; see Table 1 for details.
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women randomized to calcium plus cholecalciferol
supplements compared with placebo in this large, double-
blinded, placebo-controlled clinical trial. However, the
effect was seen primarily for women whose total cal-
cium intakes were lower than 1200 mg/d, the current RDI
for women this age.
Our findings of calcium plus cholecalciferol for long-
term weight maintenance support some11,15-18,20,24 but not
all19 of the previous studies, suggesting an inverse asso-
ciation between calcium intake and body weight. The Na-
tional Health and Nutrition Examination Survey III re-
ported that, compared with adult women in the lowest
quartile of calcium intake, those in the top quartile had
an 85% reduced risk of obesity.11 The Coronary Artery
Risk Development in Young Adults study18 reported that
baseline dairy intake was inversely associated with BMI
and that throughout the 10-year follow-up of this co-
hort, each daily serving of a dairy food was associated
with a 21% reduced risk of the development of insulin
resistance syndrome, a serious consequence of obesity.
In contrast, a Norwegian cross-sectional study15 re-
ported a positive association of calcium with BMI for men
and no association of calcium with BMI among women.
Two more recent reports, one from the Health Profes-
sionals Follow-up Study,19 showed no relationship be-
tween baseline or change in intake of calcium and weight
change during a 12-year follow-up, whereas another from
the Vitamins and Lifestyle cohort study20 demonstrated
that women who were currently taking individual cal-
cium supplements had a lower mean 10-year weight gain
than nonusers.
The limited experimental data in this area are incon-
clusive, with some studies21-23 demonstrating that in adults
calcium derived from either supplements or dairy prod-
ucts has no benefit, whereas other studies8,24,25 suggest a
positive role in weight management. However, many of
these experimental studies are limited by small sample
sizes or short study durations.
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Figure 2. A, Weight change by treatment assignment; B, weight change by treatment assignment and total calcium intake of less than 1200 mg (left) and
1200 mg or more (right) at baseline. R indicates calcium plus cholecalciferol (vitamin D) randomization, which occurred 1 to 2 years after baseline.
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Table 3. Odds of Weight Gain (as Opposed to Weight Loss or Weight Stable) for 3 Years After Randomization Into the Calcium
and Cholecalciferol (Vitamin D) Trial: Overall and by Subgroup
Variable
OR (95% CI)*
P Value†Weight Gain of 1-3 kg Weight Gain of3 kg
Overall effect of calcium and cholecalciferol 0.95 (0.90-1.01) 0.94 (0.90-0.99) .05‡
Age, y .18
50-54 0.88 (0.75-1.03) 0.92 (0.81-1.05)
55-59 0.96 (0.85-1.09) 1.00 (0.90-1.10)
60-69 0.97 (0.89-1.05) 0.94 (0.87-1.01)
70-79 0.96 (0.84-1.10) 0.87 (0.76-0.99)
Race .52
White 0.96 (0.90-1.02) 0.94 (0.89-0.99)
Black 0.95 (0.78-1.16) 0.92 (0.78-1.09)
Hispanic 0.94 (0.70-1.27) 0.92 (0.72-1.19)
Asian 0.89 (0.61-1.29) 0.82 (0.56-1.22)
American Indian 0.65 (0.25-1.65) 0.74 (0.33-1.67)
Unknown 1.10 (0.65-1.86) 1.85 (1.14-3.00)
Educational level .98
High school 0.97 (0.86-1.10) 0.96 (0.87-1.07)
School after high school§ 0.96 (0.87-1.05) 0.93 (0.86-1.01)
College degree 0.95 (0.86-1.04) 0.95 (0.87-1.03)
BMI .27
25 0.97 (0.88-1.08) 0.99 (0.90-1.09)
25 to30 0.98 (0.89-1.07) 0.93 (0.85-1.01)
30 to35 0.95 (0.83-1.08) 0.93 (0.84-1.04)
35 0.88 (0.74-1.05) 0.88 (0.77-1.01)
Waist circumference, cm .93
88 0.93 (0.86-1.00) 0.93 (0.86-1.00)
88 0.99 (0.91-1.09) 0.96 (0.89-1.03)
Total calcium intake (dietary and supplements), mg .008
1200 0.89 (0.83-0.96) 0.89 (0.84-0.95)
1200 1.05 (0.96-1.15) 1.01 (0.93-1.10)
Total cholecalciferol intake (dietary and supplements), IU .41
400 0.92 (0.85-0.99) 0.94 (0.88-1.00)
400 0.99 (0.91-1.08) 0.94 (0.87-1.02)
Energy intake, kcal .59
1382.1 0.92 (0.83-1.01) 0.93 (0.85-1.01)
1382.1-1909.5 0.93 (0.85-1.03) 0.90 (0.83-0.99)
1909.5 1.00 (0.91-1.11) 0.99 (0.91-1.08)
Energy from fat, % .25
33.5 0.88 (0.79-0.97) 0.95 (0.87-1.04)
33.5-38.5 1.02 (0.92-1.13) 0.95 (0.86-1.03)
38.5 0.97 (0.87-1.07) 0.92 (0.84-1.00)
Fruits and vegetables, medium servings per day .70
2.7 1.02 (0.92-1.13) 0.95 (0.87-1.04)
2.7-4.3 0.87 (0.79-0.97) 0.90 (0.82-0.98)
4.3 0.98 (0.88-1.08) 0.96 (0.88-1.05)
Smoking status .66
Never 0.93 (0.86-1.01) 0.95 (0.88-1.01)
Past 0.98 (0.90-1.08) 0.95 (0.88-1.03)
Current 0.90 (0.72-1.13) 0.84 (0.70-1.01)
Physical activity, METs/wk .49
3 1.00 (0.90-1.12) 0.90 (0.82-0.99)
3-11.75 0.89 (0.80-0.99) 0.93 (0.84-1.01)
11.75 0.97 (0.88-1.07) 0.99 (0.90-1.08)
DM arm  .34
Control 0.94 (0.87-1.03) 0.93 (0.86-1.01)
Intervention 1.04 (0.92-1.16) 1.01 (0.91-1.11)
HT arm¶ .34
E alone 0.94 (0.76-1.15) 0.89 (0.75-1.06)
E alone placebo 0.81 (0.66-0.98) 0.83 (0.70-0.99)
E and P 0.98 (0.84-1.14) 1.06 (0.92-1.21)
E and P placebo 0.99 (0.85-1.16) 0.96 (0.84-1.11)
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by the square of height in meters); CI, confidence interval; DM, dietary
modification; E, estrogen; HT, hormone therapy; METs, metabolic equivalents; OR, odds ratio; P, progesterone.
*Odds of gaining weight divided by odds of losing weight or remaining weight stable.
†2 Test of interaction between calcium and cholecalciferol randomized treatment and variable of interest from a nominal generalized logistic regression model.
‡2 Test of main effect of calcium and cholecalciferol randomized treatment from a nominal generalized logistic regression model.
§Includes vocational or training school after high school graduation or some college or associate’s degree.
Subset (n = 25 210) of the calcium and cholecalciferol randomized trial; see Table 1 for details.
¶Subset (n = 16 089) of the calcium and cholecalciferol randomized trial; see Table 1 for details.
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The small magnitude of the effect observed in this study
has several possible explanations. The benefit of cal-
cium on weight maintenance may, in fact, be small and
detected in this trial only because of our large sample size.
Others have also proposed that the benefit of calcium in
the absence of an energy deficit is likely to be small.
Heaney et al28 summarized data from 9 studies of cal-
cium intake in which body weight could be assessed as
a secondary outcome, concluding that in middle-aged and
older women a calcium intake difference of 300 mg/d (ap-
proximately 1 dairy serving) is associated with a de-
creased weight gain of 0.11 to 0.16 kg/y. Additionally,
based on the observation that calcium affects fecal fat ex-
cretion in a dose-dependent fashion, Welberg et al29 pre-
dicted that supplementation of 2 g/d of elemental cal-
cium as calcium carbonate might result in a change of
body weight of approximately-0.4 kg/y. In contrast to the
conclusions from the studies cited herein, both of which
are predictions based on studies of shorter durations, the
effect observed in the WHI at year 1 was not cumulative
during the 7 years of observation but appeared to peak
by year 3 and then stabilize.
Alternatively, the relatively small effect observed in
the WHI may have been because the source of calcium
supplementation was from nondairy products. This find-
ing is supported by several studies13,30 that showed larger
beneficial effects from calcium derived from consump-
tion of dairy products compared with supplements. It is
also possible that the effects of calcium may be en-
hanced under conditions of energy deficit, and larger dif-
ferences between the intervention and control groups may
have been seen if supplementation was accompanied by
energy restriction or increased energy output. One re-
cent study,31 which demonstrated that a dairy-based high-
calcium diet increased fat oxidation under conditions of
acute energy deficit, proposed that the effects were due
to an increase in exercise. In our data, we saw no inter-
action across baseline levels of physical activity or en-
ergy intakes.
This investigation has some notable limitations. First,
the WHI obtained repeated measures of anthropometry
(eg, dual-energy x-ray absorptiometry and waist circum-
ference) only on a small subset of women; we were there-
fore unable to identify whether observed weight changes
were due to changes in fat mass or other critical compo-
nents of body composition. Second, we were unable to
adequately examine whether the effect of the interven-
tion varied by baseline vitamin D status, since we did not
routinely conduct serum concentrations of 25-
hydroxyvitamin D, the preferred measure of vitamin D
status. Several studies32-35 have demonstrated lower lev-
els of 25-hydroxyvitamin D among obese compared with
nonobese individuals, suggesting a possible role for vi-
tamin D in weight. However, the strengths of this study
are considerable. To our knowledge, this is the largest
double-blind, placebo-controlled clinical trial to report
the effects of calcium plus cholecalciferol supplementa-
tion on weight change. Our long study duration of 7 years
allowed us to collect multiple weight measurements using
a standardized protocol that enabled precise measures of
weight change during the entire follow-up period. It also
allowed us to see the true trajectory of weight change
rather than the extrapolated magnitude of yearly weight
change reported in previous studies of shorter dura-
tions. Moreover, the large sample size of women pro-
vided ample power to detect small differences in weight
change, and the postmenopausal population allowed us
to generalize to a group of women for whom slow but
steady weight gain can be a common health concern.
In conclusion, even though the overall mean weight
change difference between groups was small (−0.13 kg),
women in the active intervention who had inadequate base-
line dietary calcium had an 11% lower risk of weight gain
during the first 3 years of the trial compared with women
with calcium-deficient diets in the placebo group, a more
compelling finding. Prevention of weight gain is an im-
portant public health goal, and caloric restriction and daily
physical activity should still be considered the basic te-
nets of weight management. Further research should be un-
dertaken to address the effect of calcium supplementation
combined with caloric restriction and physical activity on
weight gain prevention. Our findings do not alter current
dietary recommendations. Postmenopausal women should
continue to be advised to consume 1200 mg/d of calcium
as recommended by of the Food and Nutrition Board of
the National Academy of Sciences.36
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